

# Orphan Medical Incorporated

[View the current Orphan Medical Incorporated Page on BioPortfolio.com](http://www.bioportfolio.com/biocorporate/7917-Orphan+Medical+Incorporated.html)

(<http://www.bioportfolio.com/biocorporate/7917-Orphan+Medical+Incorporated.html>)

## Contact Details:

13911 Ridgedale Drive, Suite 475

Minnetonka

MN

55305

United States of America

Tel: 612 513 6900

Fax:

Email:

Orphan Medical Incorporated is a development stage company, was formed to acquire, develop and market products of high medical value intended to address inadequately treated or uncommon diseases of well-defined patient population treated by health care specialists. A drug has high medical value if it offers a major improvement in the safety or efficacy of patient treatment and has no substantially equivalent substitute.

## Recent Publications by Orphan Medical Incorporated:



- [The clinical development of gamma-hydroxybutyrate \(GHB\).](#)  
*The discovery of gamma-hydroxybutyrate (GHB) over 40 years ago led to its...*3rd September, 2008  
Orphan Medical, Inc., A subsidiary of Jazz Pharmaceuticals, Inc., Palo- Curr Drug Saf. 2006  
Jan;1(1):99-106.
- [Further evidence supporting the use of sodium oxybate for the treatment of cataplexy: a double-blind, placebo-controlled study in 228 patients.](#)  
*BACKGROUND AND PURPOSE: To measure the effect of the nocturnal...*8th February, 2006  
Orphan Medical, Inc., 13911 Ridgedale Drive Suite 250, Minnetonka, MN- Sleep Med. 2005  
Sep;6(5):415-21. ([DOI Direct Link](#))
- [Pharmacotherapy for cataplexy.](#)  
*A variety of medications representing several major drug classes improve...*29th January, 2005  
Orphan Medical, Inc., Medical Affairs, 13911 Ridgedale Drive, Suite 250,- Sleep Med Rev. 2004  
Oct;8(5):355-66. ([DOI Direct Link](#))
- [The Xyrem risk management program.](#)  
*Sodium oxybate, also known as gamma-hydroxybutyric acid (GHB), was...*13th August, 2004  
Orphan Medical Inc., Minnetonka, Minnesota 55305, USA.- Drug Saf. 2004;27(5):293-306.

- [The pharmacokinetics of sodium oxybate oral solution following acute and chronic administration to narcoleptic patients.](#)  
This trial was conducted to evaluate the pharmacokinetics and safety of a...15th June, 2004  
Orphan Medical, Inc., 13911 Ridgedale Drive, Suite 250, Minnetonka, MN- J Clin Pharmacol. 2004 Mar;44(3):253-7. ([DOI Direct Link](#))
- [From club drug to orphan drug: sodium oxybate \(Xyrem\) for the treatment of cataplexy.](#)  
Narcolepsy, a rare disease with a prevalence of 0.05% in the general...11th February, 2004  
Orphan Medical, Inc., Minnetonka, Minnesota 55305, USA.- Pharmacotherapy. 2003 Sep;23(9):1205-9.
- [The influence of gender and food on the pharmacokinetics of sodium oxybate oral solution in healthy subjects.](#)  
Sodium oxybate (Xyrem; gamma-hydroxybutyrate) oral solution was recently...15th March, 2003  
Orphan Medical, Inc., 13911 Ridgedale Drive, Suite 250, Minnetonka, MN- J Clin Pharmacol. 2003 Jan;43(1):59-65.
- [Sodium oxybate \(GHB\) for treatment of cataplexy.](#)  
Sodium oxybate (Xyrem; gamma-hydroxybutyrate) oral solution was recently...12th December, 2002  
Orphan Medical, Inc., Minnetonka, Minnesota 55305, USA.- Pharmacotherapy. 2002 Jun;22(6):798-9; discussion 799.

#### Press Releases on Orphan Medical Incorporated:

<a href="#">Varian Medical Systems to Highlight the Latest Digital Detectors, X-ray Tubes and Cancer Treatment Technology at the Radiological Society of North America (RSNA) Annual Meeting in Chicago</a>	27th November, 2009	Varian Medical Systems, Inc.	FOR INFORMATION CONTACT: Elaine Fairless, Varian Medical Systems 801-978-5715 elaine.fairless@varian.com SOURCE Varian Medical Systems, Inc.
<a href="#">Why Some Vaccines May Require A Booster</a>	27th November, 2009	Rochester General Health System	ROCHESTER, N.Y., Nov. 27 /PRNewswire-USNewswire/ -- Preventing disease is the goal of every health care provider and fortunately every year, new vaccines are being added to assist in disease
<a href="#">Infection-Control Strategies at Leading Hospital Can be Adapted for Everyday Use</a>	27th November, 2009	Hospital for Special Surgery	NEW YORK, Nov. 27 /PRNewswire/ -- With cold and flu season upon us, it's more important than ever to employ good practices to control the spread of infections and avoid illness. "We need to
<a href="#">New Hologic SecurView(R) DX Diagnostic Workstation Software Streamlines Workflow, Improves Radiologist Productivity</a>	25th November, 2009	Hologic, Inc.	BEDFORD, Mass., Nov. 25 /PRNewswire-FirstCall/ -- Hologic, Inc. (Hologic or the Company) (Nasdaq: HOLX), a leading developer, manufacturer and supplier of premium diagnostics, medical imaging systems

[Sentinelle Medical  
Launches Aegis Suite of  
Oncology 4D Visualization  
Software with  
PureWeb\(TM\) Technology](#)

25th November,  
2009

Sentinelle Medical  
Inc.

TORONTO, Nov. 25 /PRNewswire/ -  
Sentinelle Medical Inc., a leading  
manufacturer of breast MRI coils and  
advanced visualization software  
launches a suite of new leading edge  
clinical applications on

## BioNews Results for Orphan Medical Incorporated



- [Medical News: Advanced Cell Technology Files IND With FDA For First Human Clinical Trial Using Embryonic Stem Cells To Treat Eye Disease](#)  
*BioFind: Nov 21 2009 1:02PM Matching: orphan medical*
- [Proteo Inc./Proteo Biotech AG: European Medicines Agency EMEA Recommends Orphan Drug Status for Elafin in the Treatment of Esophagus Carcinoma](#)  
*Individual.com: Nov 17 2009 9:56AM Matching: orphan medical*
- [Proteo Inc./Proteo Biotech AG: European Medicines Agency EMEA Recommends Orphan Drug Status for Elafin in the](#)  
*StockHouse USA: Nov 16 2009 10:09AM Matching: orphan medical*
- [Proteo Inc./Proteo Biotech AG: European Medicines Agency EMEA Recommends Orphan Drug Status for Elafin in the](#)  
*Pharma Live: Nov 16 2009 8:33PM Matching: orphan medical*
- [Proteo Inc./Proteo Biotech AG: European Medicines Agency EMEA Recommends Orphan Drug Status for Elafin in the](#)  
*NewsBlaze: Nov 16 2009 11:23AM Matching: orphan medical*
- [Proteo Inc./Proteo Biotech AG: European Medicines Agency EMEA Recommends Orphan Drug Status for...](#)  
*Forbes.com: Nov 16 2009 10:01AM Matching: orphan medical*
- [Proteo Inc./Proteo Biotech AG: European Medicines Agency EMEA Recommends Orphan Drug Status for Elafin in the Treatment of Esophagus Carcinoma](#)  
*Business Wire UK: Nov 16 2009 9:58AM Matching: orphan medical*
- [Proteo Inc./Proteo Biotech AG: European Medicines Agency EMEA Recommends Orphan Drug Status for Elafin in the](#)  
*Street Insider: Nov 16 2009 9:57AM Matching: orphan medical*
- [Proteo Inc./Proteo Biotech AG: European Medicines Agency EMEA Recommends Orphan Drug Status for Elafin in the](#)  
*Business Wire: Nov 16 2009 9:55AM Matching: orphan medical*
- [Proteo Inc./Proteo Biotech AG: European Medicines Agency EMEA Recommends Orphan Drug Status for Elafin in the](#)  
*Business Wire via Yahoo!: Nov 16 2009 9:53AM Matching: orphan medical*
- [Proteo's Elafin recommended for orphan drug status in Europe](#)  
*News-Medical.Net: Nov 16 2009 12:51PM Matching: orphan medical*
- [Proteo Inc./Proteo Biotech AG: European Medicines Agency EMEA Recommends Orphan Drug Status for Elafin in the Treatment of Esophagus Carcinoma](#)  
*Stockwatch: Nov 16 2009 10:00AM Matching: orphan medical*
- [Proteo Inc./Proteo Biotech AG: European Medicines Agency EMEA Recommends Orphan Drug Status for Elafin in](#)  
*PR inside: Nov 16 2009 9:58AM Matching: orphan medical*

- [Proteo Inc./Proteo Biotech AG: European Medicines Agency EMEA Recommends Orphan Drug Status for Elafin in the](#)  
*RBC Dain Rauscher: Nov 16 2009 9:54AM Matching: orphan medical*
- [Proteo Inc./Proteo Biotech AG: European Medicines Agency EMEA Recommends Orphan Drug Status for Elafin in the](#)  
*Yahoo! Canada: Nov 16 2009 9:50AM Matching: orphan medical*

#### Orphan Medical Incorporated Clinical Trials:



- [Safety and Efficacy of Xyrem Oral Solution \(Sodium Oxybate\) Compared With Placebo in Narcoleptic Patients](#)

#### Orphan Medical Incorporated Patents:



- 7572605- [Gamma-hydroxybutyrate compositions containing carbohydrate, lipid or amino acid carriers](#)
- 7262219- [Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy](#)
- 7015200- [Gamma-hydroxybutyrate compositions containing carbohydrate, lipid or amino acid carriers](#)
- 6780889- [Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy](#)
- 6472431- [Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy](#)
- 6210666- [Truncated .alpha.-galactosidase A to treat fabry disease](#)
- 5990162- [Method for treatment of fibromyalgia and chronic fatigue syndrome](#)

## BioCorporate Profiles - upgrade to a full profile

BioPortfolio's BioCorporate full profiles offers your organization the opportunity to increase internet traffic to your corporate web site and enhance awareness of your business, technology, products and services. BioCorporate profiles are dynamic and are updated weekly with new information sourced from core information resources: publications, clinical trials, patents and global news.

Why you should upgrade your BioPortfolio BioCorporate profile:

- the ability to amend and add information on products and services to your profile using a membership

username and password

- the option to add a corporate logo
- the creation of high value URL links back to your organization's website which will improve search engine ranking - resulting in increased site traffic
- the option have your press releases published on BioPortfolio and distributed via our BioNewsCast service
- an enhanced BioCorporate profile will also improve your exposure on BioPortfolio's related service InDepth and GeneDB

The annual cost is \$995.00 for established organizations and \$495.00 for organizations less than 12 months old.

\*\*\*

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2009 - BioPortfolio Limited.

